Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 13, 2026

Small Molecule Innovator API CDMO Market Outlook, 2026-2033 - Lonza Group, Novo Holdings (Catalent) and Thermo Fisher Scientific Lead the Growing Industry

View original at finance.yahoo.com
Small Molecule Innovator API CDMO Market Outlook, 2026-2033 - Lonza Group, Novo Holdings (Catalent) and Thermo Fisher Scientific Lead the Growing Industry Company Logo With a focus on specialty medicines, growth is driven by pharmaceutical needs for cost-effective, efficient production and regulatory compliance via CDM…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The global small molecule innovator API CDMO market is projected to expand significantly, with an estimated size of USD 26.66 billion in 2025, expected to reach USD 43.75 billion by 2033, growing at a CAGR of 6.55% from 2026 to 2033

    60% confidence

  • Only 11% of APIs are based in the U.S., with most sourced internationally

    60% confidence

  • By February 2024, the global tally of registered clinical trials on ClinicalTrials.gov reached 483,592, marking a significant rise from the over 365,000 reported in early 2021. Of these, 66,206 trials are actively recruiting

    60% confidence

  • Market expansion is fueled by a growing demand for small molecule drugs, an increase in outsourcing trends among pharmaceutical companies, and a surge in clinical trials

    60% confidence

  • Small molecule applications constitute over half of specialty sales

    60% confidence

Data points we hold from this source

U.S. Food and Drug Administration · drug approvals46 novel_drugs
U.S. Food and Drug Administration · drug approvals50 novel_drugs
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com